forecast some of the factors that contributed to our over performance in the first half to ease towards the end of the year we look forward to a strong H2. On the cost side we face some headwinds in variable
majority of the audit firms push forward to increase auditors in the capital market, thus support the increasing number of listed companies. Therefore, the ratio of listed companies to auditors in the
, our revenue from sales amounted to THB 12,904 million, up by THB 2,961 million or 29.8% divided into the proportion of revenue from domestic sales and revenue from overseas sales at 61:39 respectively
selling medical equipment 60.65 73.92 Administrative expenses 109.64 105.99 Finance costs 22.86 24.24 Finance costs (net) 20.87 21.71 Proportion of cost of medical treatment / revenue of medical treatment
590.59 553.11 Cost of selling medical equipment 65.30 57.70 Administrative expenses 112.97 109.49 Finance costs 19.32 24.93 Finance costs (net) 16.90 22.87 Proportion of cost of medical treatment / revenue
Company shall subscribe the newly issued share in proportion of 108,022 shares and the newly issued share in portion of the unsubscribed shares of other shareholders of 40,604 shares. As subscription of
Representative Office Abroad Securities Company / Derivatives Intermediary 23/07/2013 3. Notification of the Office of the Securities and Exchange Commission OrThor. 12/2543 Re: Moving of the Securities
expenses. In Q3/2017 the Company recorded the Baht 5.38 million After moving the production equipment to Prachinburi plant and utilizing the plant to produce the product, the production cost has been lowered